Analyst Ratings For NASDAQ:PTLA – Portola Pharmaceuticals (NASDAQ:PTLA)
Today, Morgan Stanley reiterated its Positive ➝ Equal Weight rating on NASDAQ:PTLA – Portola Pharmaceuticals (NASDAQ:PTLA) with a price target of $46.00.
Some recent analyst ratings include
- 5/7/2018-Morgan Stanley Reiterated Rating of Positive ➝ Equal Weight.
- 3/13/2018-William Blair Reiterated Rating of Buy.
- 3/13/2018-Credit Suisse Group Reiterated Rating of Outperform ➝ Outperform.
- 12/1/2017-Goldman Sachs initiated coverage with a Buy ➝ Buy rating.
Recent Insider Trading Activity For NASDAQ:PTLA – Portola Pharmaceuticals (NASDAQ:PTLA)
NASDAQ:PTLA – Portola Pharmaceuticals (NASDAQ:PTLA) has insider ownership of 4.60% and institutional ownership of 86.53%.
- On 3/12/2018 Tao Fu, EVP, sold 1,135 with an average share price of $38.47 per share and the total transaction amounting to $43,663.45.
- On 12/15/2017 Henry Ward Wolff, Director, sold 12,000 with an average share price of $47.00 per share and the total transaction amounting to $564,000.00.
- On 7/18/2017 John T. Curnutte, Insider, sold 10,000 with an average share price of $65.00 per share and the total transaction amounting to $650,000.00.
- On 7/18/2017 Tao Fu, EVP, sold 5,812 with an average share price of $65.00 per share and the total transaction amounting to $377,780.00.
- On 7/11/2017 Mardi Dier, VP, sold 23,350 with an average share price of $60.00 per share and the total transaction amounting to $1,401,000.00.
- On 6/28/2017 William Lis, CEO, sold 269,299 with an average share price of $55.43 per share and the total transaction amounting to $14,927,243.57.
- On 6/27/2017 Mardi Dier, VP, sold 93,392 with an average share price of $55.46 per share and the total transaction amounting to $5,179,520.32.
Recent Trading Activity for NASDAQ:PTLA – Portola Pharmaceuticals (NASDAQ:PTLA)
Shares of NASDAQ:PTLA – Portola Pharmaceuticals closed the previous trading session at 41.13 down -1.31 3.09% with shares trading hands.